
9th Annual World Cancer Series: Day 2
As Economist Impact’s World Cancer Series continues, Day Two firmly takes up focus on the patient voice, with a presentation by Eileen Page, chief executive of Innovation Advantage 2020 to

Company Profile: Healthcare Consultancy Group
CEO/President Matt D’Auria Headquarters

How AI-powered adaptive design helped Eisai launch Leqembi
In July, when the FDA approved Eisai and Biogen’s Alzheimer’s drug Leqembi, we noted the historic natu

Cancer Research UK earmarks £123m for Scottish R&D
Cancer Research UK (CRUK) has said it will award £123 million ($150 million) in funding over the next seven years to Scotland’s Beatson Institute, which will be renamed th

Menarini brings oral SERD to Europe with Orserdu okay
Menarini has secured EU approval for Orserdu, the first in a new class of oral selective oestrogen receptor degrader (SERD) drugs and the first innovation in endocrine the
Featured Content
Editor's Picks
Editor's Picks
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content

Research2Guidance launches Allis.Health, a new digital healt...
(Berlin, Germany and Salerno, Italy) - On September 18th, 2023, Allis.Health, a new digital health analyst platform, offi

Amar Urhekar joins FH as Chief Operating Officer
WASHINGTON, D.C., Sept.

2nd Innate Killer Europe Summit
The 2nd Innate Killer Europe Summit will gather 80+ key European Gamma Delta T, NK, iNKT, neutrophil, and macrophage developers in October to chase the holy grail of efficacious, off-the-sh

3rd Synthetic Biology-Based Therapeutics Summit
The 3rd Synthetic Biology-Based Therapeutics Summit is a platform uniting academia, engineers, and drug developers working towards increased specificity, durability and potency.

3rd ADC Target Selection Summit
The 3rd ADC Target Selection Summit (December 5-7 | Boston, MA).